Fit for health 2.0, introduction to H2020

Introduction to Horizon 2020
15.05.2014 | TUNIS
Nicolas Villacorta | Management Jülich
dr Frank Heemskerk

15.052014
TUNIS
EU Funding for Research and Innovation
Driven by EU politics
(Europe 2020 Strategy)
Funding of single
researchers and research
consortia
Pool and exchange
knowlegde and
experience
Projects with partners from different
disciplines and sectors
EU funding based on
subsidy principle
Funding from basic
research to close-to-
market activities
Enhance your reputation
Compare your
achievements on
international level
Collaboration with
partners in Europe and
beyond
2
© Fit for Health 2.0, 2014

15.052014
TUNIS
Overview of Horizon 2020
 Public largest international, competitive, cooperative Research & Innovation
Programme for the period 2014-2020
 Leading instrument for the implementation of the European Research Area
 Specific programme: pre-defined thematic areas
 Supports competitiveness in Europe
 Beyond Europe: International Cooperation
HORIZON 2020
3

15.052014
TUNIS
New in Horizon 2020
 A single programme bringing together three separate
programmes/initiatives: FP7 + CIP + EIT*
 More innovation: from research to commercialisation of all
forms of innovation
 Focus on societal challenges faced by EU society including health, food security,
clean energy and transport
 Simplified access for all companies, universities, institutes in all EU countries and
beyond.
* The 7th research Framework Programme (FP7), innovation aspects of
Competitiveness and Innovation Framework Programme (CIP), EU contribution
to the European Institute of Innovation and Technology (EIT)
4

15.052014
TUNIS
Structure of Horizon 2020
Source: www.eubuero.de. Simplified nomenclature
I. Excellent Science
II. Industrial
Leadership
III. Societal
Challenges
LEIT
Leadership in Enabling and
Industrial Technologies:
ICT, Nanotechnology, Advanced
Materials, Biotechnology,
Production Technology, Space
Access to Risk Finance
Innovation in SMEs
ERC
FET
Marie-Skłodowska-
Curie
Infrastructures
JRC
EIT
Health, Demographic Change
and Wellbeing
Challenges in the European
Bioeconomy…
Secure, clean and efficient
Energy
Smart, green and integrated
transport
Climate, environment, resource
efficiency & raw materials
Integrative, innovative and
reflective societies
Secure societies
Spreading
Excellence
Widening
Participation
Science with
and for
Society
5

15.052014
TUNIS
"direct“ Activities (JRC, nuclear)
+
SpecificProgramme
Cooperation People
Ideas Capacities
Joint Research Centre (JRC, not nuclear)
"indirect" Activities (Fusion, Fission and radiation
protection)
Framework Programme EURATOM
Source: www.eubuero.de
7th Framework Programme
6

15.052014
TUNIS
Horizon 2020 – 7th Framework Programme
FP7
II. Industrial
Leadership
III. Societal
Challenges
LEIT
ICT, Nano-
technology,
Materials,
Biotechnology,
Production technologies,
Space
Risk Finance
Innovation in SMEs
ERC
FET
MSC
INFRA
JRC
EIT
Health, DC & WB
Bioeconomy
Energy
Transport
Environment, raw materials
Societies
Security
Spreading
Excellence
Widening
Participation
Science with
and for
Society
ERC
Marie Curie
KBBE
Cooperation People
Ideas Capacities
JRC (no nuclear)
HEALTH
KBBE
Source: www.eubuero.de.
Simplified nomenclature
7

15.052014
TUNIS
Source: www.eubuero.de.
Budgetary Breakdown (EUR)
31.3%
22.09%
38.53%
1.06%
0.60%
3.52% 2.47%
Excellent Science
Industrial Leadership
Societal Challenges
Widening Participation
Science with and for Society
JRC
EIT
29.7 bn
24.4 bn.
17 bn.
1.9 bn.
2.7 bn.
0.8 bn.
0.4 bn.
For 2014-2020 : 77.0 bn. EUR (23 561 bn. HUF)
8

15.052014
TUNIS
Terminology in Horizon 2020
II. Industrial Leadership
LEIT
Leadership in Enabling and Industrial
Technologies
ICT,
Nanotechnology,
Biotechnology…
Part II,
Priority
Specific
Objective
Activity Line
Topic(s)
Next generation Computers: Advanced
calculation systems and technologies, including
Cloud Computing
9

15.052014
TUNIS
Objectives:
 Reinforce and widen excellence in science
 Consolidate the European Research Area
 Increase the global competitiveness of the research and innovation
system in Europa
Trends:
 Science-driven projects
 „bottom-up“
 Possibility of cofunding from member states
 Researchers set the research agenda
* FET = Future and Emerging Technologies
ERC
FET
Marie-Skłodowska-
Curie
Infrastructures
10

15.052014
TUNIS
European Research Council (ERC)
ERC
FET
Marie-Skłodowska-
Curie
Infrastructures
 Total budget: 11.9 bn. EUR
 Starting Grants
2-7 years after PhD,
up to 2 m. EUR for max. 5 years
 Consolidator Grants
7-12 years after PhD,
up to 2.75 m. EUR for max. 5 years
 Advanced Grants
for experienced and excellent researchers,
up to 3.5 m EUR for max. 5 years
 Synergy Grants
for consortia from two to four
excellent researchers,
up to 15 m EUR for max. 6 years
 Proof-of-Concept
for ERC Grantees to implement the
innovation dimension of a idea, (0.15 m. EUR)NCP-ERC
11

15.052014
TUNIS
Future and Emerging Technologies (FET)
ERC
FET
Marie-Skłodowska-
Curie
Infrastructures
 Total budget: 2.5 bn. EUR
 Cutting-edge research in new Technologies
 FET Open:
• Theme open, early research in technologies
through cooperative projects
 FET Proactive:
• Specific Funding for new themes
• Support for research clusters
• Setting of Communities
 FET Flagship:
• Design of a research agenda
• Research initiatives in a think-big dimension:
so far GRAPHENE und Human Brain Project
NCP-FET
12

15.052014
TUNIS
SME
SME
SME
Marie Skłodowska-Curie Actions (MSCA)
ERC
FET
Marie-Skłodowska-
Curie
Infrastructures
 Total budget: 5.6 m. EUR
 Action 1: Innovative Training Networks (ITN)
Training for PhDs
 Action 2: Individual Fellowships (IF)
Funding for experienced researchers (post-doc)
 Action 3: Research and Innovation Staff Exchange
(RISE)
Exchange of staff within cooperation projects
 Action 4: COFUND
Mechanism of co-funding for (national) mobility
programmes
NCP-MOBILITY
13

15.052014
TUNIS
Infrastructures
ERC
FET
Marie-Skłodowska-
Curie
Infrastructures
 Total budget: 2.3 m. EUR
Objectives:
 Integration existent research infrastructures
 Construction of new research organisations and
facilities of common european interest
 Funding instrument: Combination of cooperation
projects and coordination and support actions
NCP-INFRA
14

15.052014
TUNIS
II. Industrial
Leadership
LEIT
Innovation in SMEs
II. Industrial Leadership
Objectives:
 Fast-track development of technologies and innovation
 Key Enabling Technologies: KET
 Fundamentals of tomorrow‘s business
 Support of innovative european SMEs
Trends:
 Industrial strategic agendas dictate the calls
 Close-to-market activities
 Adapted conditions
 Industry with a key role
15

15.052014
TUNIS
II. Industrial
Leadership
LEIT
Innovation in SMEs
KET Biotechnology
NCP-BIO
Workprogramme of KET Biotech
 Five topics for 2014-2015
 Support of cutting-edge biotechnologies as future innovative
force
 Industrial biotechnology
 Innovative and competitive technology platforms
16

15.052014
TUNIS
II. Industrial
Leadership
LEIT
Innovation in SMEs
KET Nanotechnology: Nanomedicine
NCP-NMP
Section „Nanotechnology and Advanced Materials for a more
effective Healthcare“:
 Enable more effective therapies and diagnostics through
nanotechnologies and advanced materials
 Clinical tests of new developments are foreseen
 Industry including SMEs are key players
17

15.052014
TUNIS
II. Industrial
Leadership
LEIT
Innovation in SMEs
NCP-FINANCE
 Financial Instruments:
• Loans Service for R&I
• SMEs & Small Midcaps R&I Loans Service
• Equity Facility for R&I
• Technology Transfer Financing Facility Pilot
 External Expertise:
• Assessing the Investment Potential of SMEs Emerging from
Phase I of the SME Instrument
• Technical and Financial Advisory Service for Risk Finance in
R&I
 Studies:
• Understanding the Intellectual Property Aggregation
Marketplace
• Understanding the Nature and Impact of Angel and Crowd-
Funding in R&I
• …
http://access2eufinance.ec.europa.eu/
18

15.052014
TUNIS
II. Industrial
Leadership
LEIT
Innovation in SMEs
Innovation in SMEs
 Aim: close the gap for early phases of high risk
research and innovation
 Broad meaning of innovation: technological and
non-technological, social and service innovation (European
added-value)
 Implementation: Reference to topics with SME instrument in
other programmes
NCP-SME
19

15.052014
TUNIS
III. Societal Challenges
Objectives:
 Alignement to political Focus (Strategy EU 2020)
 Complete cycle from research to commercialisation. Focus on
innovation
 Bild critical mass – transdisciplinary research
Trends:
 Tight collaboration with other DGs during design of
workprogramme
 Coordination and completion with ERA-Nets and JPIs –
Mobilisation of complementary funding for research and
innovation
 Focus on 7 areas (Societal Challenges)
 Coverage of the complete innovation chain: research,
technological development, demonstration and innovation
activities
III. Societal
Challenges
and Wellbeing
Bioeconomy…
Energy
transport
Secure societies
20

15.052014
TUNIS
III. Societal Challenges
Objectives:
 Alignement to political Focus (Strategy EU 2020)
 Complete cycle from research to commercialisation. Focus on
innovation
 Bild critical mass – transdisciplinary research
Trends:
 Tight collaboration with other DGs during design of
workprogramme
 Coordination and completion with ERA-Nets and JPIs –
Mobilisation of complementary funding for research and
innovation
 Focus on 7 areas (Societal Challenges)
 Coverage of the complete innovation chain: research,
technological development, demonstration and innovation
activities
III. Societal
Challenges
and Wellbeing
Bioeconomy…
Energy
transport
Secure societies
NCP-HEALTH
21

15.052014
TUNIS
Participation of SMEs
 Integrated approach - around 20% of the total budget
for societal challenges and LEITs to go to SMEs
 Simplification of particular benefit to SMEs (e.g. single
entry point)
 A new SME instrument, building on the SBIR model,
will be used across all societal challenges as well as for
the LEITs
 'Access to risk finance' will have a strong SME focus
(debt and equity facility)
22

15.052014
TUNIS
Horizon 2020: Societal Challenges (SCs)
 Societal Challenges: Addressing key societal challenges
(climate, energy, transport etc) through multi-disciplinary
applied research including social sciences & humanities
Health, demographic change & wellbeing 7 472 Mio €
(current prices)
Food security, sustainable agriculture & forestry, marine &
maritime & inland water research & the Bioeconomy
3 851 Mio €
Secure, clean & efficient energy * 5 931 Mio €
Smart, green & integrated transport 6 339 Mio €
Climate action, environment, resource efficiency & raw materials 3 081 Mio €
Inclusive, innovative & reflective societies 1 310 Mio €
Secure societies 1 695 Mio €
23

15.052014
TUNIS
SC1 Work Programme: Structure
1. Personalising Health & Care (PHC)
 1.1. Understanding health, ageing & disease
 1.2. Effective health promotion, disease prevention,
preparedness & screening
 1.3. Improving diagnosis
 1.4. Innovative treatments & technologies
 1.5. Advancing active & healthy ageing
 1.6. Integrated, sustainable, citizen-centred care
 1.7. Improving health information, data exploitation & providing
an evidence base for health policies & regulation
2. Health Co-ordination activities (HCO)
3. Health Other Actions (HOA)
24

15.052014
TUNIS
SC1 Work Programme 2014-2015
Call ‘Personalising Health & Care - PHC‘
34 topics (15 open in 2014, 17 in 2015, 2 in 2014 & 2015)
Call ‘Health Co-ordination Activities - HCO‘
16 topics (11 open in 2014, 5 in 2015)
1,21
billion €
http://ec.europa.eu/research/participants/portal/doc/call/h2020/
common/1587763-08._health_wp2014-2015_en.pdf
25

15.052014
TUNIS
SC1 Work Programme 2014-2015:
Example of Call’s Topic
 'PHC 2 – 2015'
 'Specific challenge'
 'Scope'
 'Expected impact'
 'Type of action'
26

15.052014
TUNIS
Call PHC - Area 1
AREA TOPIC / YEAR ACTION BUDGET 1 or 2
STAGES
1.1 Understanding
health, ageing &
disease
PHC 1 – 2014: Understanding
health, ageing & disease:
determinants, risk factors & pathways
(4-6 Mio €)
RIA (100%) 54 Mio. € 2 stages
PHC 2 – 2015: Understanding
diseases: systems medicine (4-6 Mio
€)
PHC 3 - 2015: Understanding common
mechanisms of diseases & their
relevance in co-morbidities (4-6 Mio €)
27

15.052014
TUNIS
Call PHC – Area 2
AREA TOPIC / YEAR ACTION BUDGET 1 or 2 ST
1.2 Effective
health
promotion,
disease
prevention,
preparedness
& screening
PHC 4–2015: Health promotion & disease
prevention: improved inter-sector co-operation for
environment & health based interventions (4-6 Mio €)
PHC 5–2014: Health promotion and disease
prevention: translating ‘omics’ into stratified
approaches (4-6 Mio €)
PHC 6–2014: Evaluating existing screening and
prevention programmes (2-3 Mio €)
PHC 7–2014: Improving the control of
infectious epidemics & foodborne outbreaks
through rapid identification of pathogens (see also
SC2) (15-20 Mio €)
RIA (100%)
20 Mio. €
(15 SC1 +5
SC2)
1 stage &
hearing
PHC 8–2014: Vaccine development for poverty-
related and neglected infectious diseases:
Tuberculosis (15-20 Mio €)
RIA (100%) 25 Mio. €
1 stage &
hearing
PHC 9–2015: Vaccine development for poverty-
related and neglected infectious diseases: HIV/AIDS
(15-20 Mio €)
RIA (100%) 21 Mio. €
1 stage &
hearing
28

15.052014
TUNIS
Call PHC – Area 3
1.3
Improving
diagnosis
PHC 10 – 2014: Development of new
diagnostic tools and technologies: in vitro
devices, assays and platforms (4-6 Mio €)
PHC 11 – 2015: Development of new
diagnostic tools and technologies: in vivo
medical imaging technologies (4-6 Mio €)
PHC 12 – 2014/2015: Clinical research
for the validation of biomarkers and/or
diagnostic medical devices
(50000 € phase 1; 2-5 Mio € phase 2)
SME
(100%)
66.10 Mio. €
(2014)+ 45
Mio. € (2015)
(*10% phase 1;
88% phase 2; 2%
phase 3)
Single
stage – 2
cut off
dates
29

15.052014
TUNIS
Call PHC – Area 4
1.4
Innovative
treatments &
technologies
PHC 13 – 2014: New therapies for chronic non-
communicable diseases (4-6 Mio €)
PHC 14 – 2015: New therapies for rare diseases
(4-6 Mio €)
PHC 15 – 2014/2015: Clinical research on
regenerative medicine (4-6 Mio €) RIA (100%)
71 Mio. €
(36 (2014)+ 35
(2015))
1 stage
2014
PHC 16 – 2015: Tools and technologies for
advanced therapies (4-6 Mio €)
PHC 17 – 2014: Comparing the effectiveness
of existing healthcare interventions in the elderly
(4-6 Mio €)
PHC 18 – 2015: Establishing effectiveness of health
care interventions in the paediatric population
(4-6 Mio €)
30

15.052014
TUNIS
Call PHC – Area 5
1.5 Advancing
active &
healthy ageing
PHC 19–2014: Advancing active &
healthy ageing with ICT: Service robotics
within assisted living environments (3-4 Mio €)
RIA (100%) 24.6 Mio.€ 1 stage
PHC 20–2014: Advancing active &
healthy ageing with ICT: ICT solutions for
independent living with cognitive
impairment (2-3 Mio €)
IA (70%) 10 Mio. € 1 stage
PHC 21–2015: Advancing active and
healthy ageing with ICT: Early risk
detection and intervention (3-4 Mio €)
RIA (100%) 21 Mio. € 1 stage
PHC 22–2015: Promoting mental wellbeing
in the ageing population (4-6 Mio €)
31

15.052014
TUNIS
Call PHC – Area 6
1.6 Integrated,
sustainable,
citizen-centred
care
PHC 23–2014: Developing and comparing
new models for safe and efficient, prevention
oriented health and care systems (4-6 Mio €)
RIA (100%) 30 Mio.€ 2 stages
PHC 24–2015: Piloting personalised medicine in
health and care systems (12-15 Mio €)
PHC 25 – 2015: Advanced ICT systems and
services for Integrated Care (3-5 Mio €)
RIA (100%) 20 Mio. € 1 stage
PHC 26–2014: Self-management of health
and disease: citizen engagement and mHealth
(3-5 Mio €)
RIA (100%) 59.6 Mio. € 1 stage
PHC 27–2015: Self-management of health &
disease & patient empowerment supported by ICT
(3-5 Mio €)
PCP 15 Mio. € 1 stage
PHC 28–2015: Self-management of health &
disease & decision support systems based on
predictive computer modelling used by the patient
him or herself (3-5 Mio €)
RIA (100%) 20 Mio. € 1 stage
PHC 29–2015: Public procurement of innovative
eHealth services (1-5 Mio €)
PPI 10 Mio. € 1 stage
32

15.052014
TUNIS
Call PHC – Area 7
1.7 Improving
health
information,
data
exploitation &
providing an
evidence base
for health
policies &
regulation
PHC 30–2015: Digital representation of
health data to improve disease diagnosis and
treatment (3-5 Mio €)
RIA (100%) 20 Mio.€ 1 stage
PHC 31–2014: Foresight for health
policy development & regulation (2-3 Mio €)
RIA (100%) 6 Mio. € 1 stage
PHC 32–2014: Advancing bioinformatics
to meet biomed &clinical needs (2-3 Mio €)
PHC 33–2015: New approaches to improve
predictive human safety testing (10-15 Mio €)
PHC 34–2014: eHealth interoperability
(up to 1 Mio €)
CSA (100%) 4 Mio. € 1 stage
33

Fit for health 2.0, introduction to H2020

More Related Content

What's hot (19)

Viewers also liked (20)

Similar to Fit for health 2.0, introduction to H2020 (20)

More from Pasteur_Tunis (20)

Recently uploaded (20)

Fit for health 2.0, introduction to H2020